Michael Sumner compensation by year
INOVIO PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $532,000 | $548,708 |
| Bonus | $47,133 | $0 |
| Stock awards | $139,596 | $127,607 |
| Option awards | $136,320 | $129,554 |
| Non-equity incentive | $167,107 | $87,392 |
| Pension and deferred compensation | $0 | $0 |
| All other | $15,250 | $17,375 |
| Total | $1,037,406 | $910,636 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: INOVIO PHARMACEUTICALS, INC. DEF 14A filed April 7, 2026, accession 0001055726-26-000011, and prior-year filings.
How this page was built: the INOVIO PHARMACEUTICALS, INC. filed document, accession 0001055726-26-000011. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 34,650 | $60,291 | — |
| RSU | 28,350 | $49,329 | — |
| RSU | 10,019 | $17,433 | — |
| PSU | 4,984 | $8,672 | — |
| RSU | 4,292 | $7,468 | — |
| PSU | 2,670 | $4,646 | — |
| RSU | 2,385 | $4,150 | — |
| Option | 9,374 | — | $8.46 |
| Option | 2,343 | — | $14.88 |
| Option | 5,708 | — | $1.78 |
| Option | 21,450 | — | $1.94 |
| Option | 35,100 | — | $2.13 |
Per the Outstanding Equity Awards at Fiscal Year-End table in INOVIO PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
INOVIO PHARMACEUTICALS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Jacqueline Shea | President, Chief Executive Officer and Director | $1,587,155 |
| Michael Sumner · this page | Chief Medical Officer and Head of Development | $910,636 |
| Peter Kies | Chief Financial Officer | $833,684 |
Michael Sumner's compensation dossier, INOVIO PHARMACEUTICALS
You have read Michael Sumner's totals and holdings. The dossier adds each equity grant INOVIO PHARMACEUTICALS disclosed for Michael Sumner and INOVIO PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full INOVIO PHARMACEUTICALS compensation record
free company briefThis page is one person within INOVIO PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the INOVIO PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order INOVIO PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are INOVIO PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.